Trajectory of MS disease course for men and women over three eras

Abstract

Background:

Heterogeneity in disease course exists within multiple sclerosis (MS) subtypes.

Objective:

The objective was to estimate disease course heterogeneity over three distinct onset periods (pre-1995, 1995–2004, and 2005–present) for men and women.

Methods:

Group-based trajectory model (GBTM) was used to estimate clusters of patients following stable or unstable disease progression trajectories based on the Expanded Disability Status Scale (EDSS). Inception cohorts were generated from the Montreal Neurological Institute MS Clinic registry. Stable trajectories were defined as an EDSS ⩽3.0 and change ⩽1 point over the study period. Annualized relapse rate (ARR) based on the first 5 years of disease was an explanatory variable.

Results:

Proportion of women classified as stable was 0% for pre-1995, 69.0% for 1995–2004, and 83.9% post-2005; for men, these proportions were 18.4%, 41.4%, and 53.8%, respectively. Men had lower percentage of stable disease than women in both post-1995 cohorts (chi-square p < 0.0001). ARR was associated with higher disability trajectories in both post-1995 cohort (odds ratios >1.0) but not in the pre-1995 cohort.

Conclusion:

Large proportions of patients remain stable at their initial disability level for at least 15 years. Higher ARR increases the odds of patients being in a higher disability trajectory in the latter cohorts.

Keywords

Multiple sclerosis disease course epidemiology

Get full access to this article

View all access options for this article.

References

Minderhoud

van der Hoeven

Prange

. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand 1988; 78(1): 10–15.

Lublin

Reingold

. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996; 46: 907–911.

Lublin

Reingold

Cohen

. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83(3): 278–286.

Confavreux

Compston

. Chapter 4: The natural history of multiple sclerosis. In: Compston

(ed.) McAlpine’s multiple sclerosis. 4th ed. Edinburgh: Churchill Livingstone, 2006, pp. 183–272.

Singer

Willett

. Applied longitudinal data analysis: Modeling change and event occurrence. New York: Oxford University Press, 2003.

Nagin

. Group-based modeling of development. Cambridge: Harvard University Press, 2005.

Nagin

Odgers

. Group-based trajectory modeling in clinical research. Ann Rev Clin Psychol 2010; 6(1): 109–138.

Kappos

Lechner-Scott

Lienert

. Neurostatus.net, 2007.

Twisk

Hoekstra

. Classifying developmental trajectories over time should be done with great caution: A comparison between methods. J Clin Epidemiol 2012; 65(10): 1078–1087.

10.

Salas

Hotman

Stricker

. Confounding by indication: An example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149(11): 981–983.

11.

Tremlett

Zhao

Joseph

.; The UCN. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatr 2008; 79(12): 1368–1374.

12.

Van Dulmen

MHM

Goncy

Vest

. Group-based trajectory modeling of externalizing behavior problems from childhood through adulthood: Exploring discrepancies in the empirical findings. In: Savage

(ed.) The development of persistent criminality. New York: Oxford University Press, 2009, pp. 289–314.

13.

Richards

Sampson

Beard

. A review of the natural history and epidemiology of multiple sclerosis: Implications for resource allocation and health economic models. Health Technol Assessment 2002; 6(10): 1–73.

14.

Tremlett

Zhao

Rieckmann

. New perspectives in the natural history of multiple sclerosis. Neurology 2010; 74(24): 2004–2015.

15.

Ramsaransing

GSM

De Keyser

. Benign course in multiple sclerosis: A review. Acta Neurol Scand 2006; 113(6): 359–369.

16.

Sayao

A-L

Devonshire

Tremlett

. Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 2007; 68: 496–500.

17.

Hutchinson

. Disability due to multiple sclerosis: A community-based study of an Irish county. Irish Med J 1986; 79: 48–50.

18.

Cabre

Heinzlef

Merle

. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001; 56(4): 507–514.

19.

Thompson

Hutchinson

Brazil

. A clinical and laboratory study of benign multiple sclerosis. QJM 1986; 58(1): 69–80.

20.

McDonnell

Hawkins

. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 1998; 50(2): 423–428.

21.

Bencsik

Rajda

Füvesi

. The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrád County, Hungary. Eur Neurol 2001; 46(4): 206–209.

22.

Kalanie

Gharagozli

Kalanie

. Multiple sclerosis: Report on 200 cases from Iran. Mult Scler 2003; 9(1): 36–38.

23.

Leray

Yaouanq

Le Page

. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133(7): 1900–1913.

24.

Confavreux

Vukusic

Adeleine

. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003; 126: 770–782.

25.

Runmarker

Andersen

. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116(1): 117–134.

26.

Scalfari

Neuhaus

Degenhardt

. The natural history of multiple sclerosis, a geographically based study 10: Relapses and long-term disability. Brain 2010; 133(7): 1914–1929.

27.

Tremlett

Yousefi

Devonshire

.; UBC Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73(20): 1616–1623.

28.

Mayo

Bronstein

Scott

. Necessary and sufficient causes of participation post-stroke: Practical and philosophical perspectives. Qual Life Res 2014; 23(1): 39–47.

29.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444–1452.

30.

Porta

. Dictionary of epidemiology. 5th ed. New York: Oxford University Press, 2008.

31.

Wolfson

. The latent period of multiple sclerosis: A critical review. Epidemiology 1993; 4(5): 464–470.

32.

Everitt

. The Cambridge dictionary of statistics. Cambridge: Cambridge University Press, 2006.

33.

Poser

Paty

Scheinberg

. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13(3): 227–231.

34.

McDonald

Compston

Edan

. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121–127.

35.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005; 58: 840–846.

36.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292–302.

37.

Marrie

Cutter

Tyry

. Changes in the ascertainment of multiple sclerosis. Neurology 2005; 65(7): 1066–1070.

38.

Nixon

Bergvall

Tomic

. No evidence of disease activity: Indirect comparisons of oral therapies for the treatment of relapsing–remitting multiple sclerosis. Adv Ther 2014; 31(11):1134–1154.